WO1999043339A1 - A pharmaceutical preparation comprising an angiotensin ii type 2 receptor agonist, and use thereof - Google Patents

A pharmaceutical preparation comprising an angiotensin ii type 2 receptor agonist, and use thereof Download PDF

Info

Publication number
WO1999043339A1
WO1999043339A1 PCT/SE1999/000262 SE9900262W WO9943339A1 WO 1999043339 A1 WO1999043339 A1 WO 1999043339A1 SE 9900262 W SE9900262 W SE 9900262W WO 9943339 A1 WO9943339 A1 WO 9943339A1
Authority
WO
WIPO (PCT)
Prior art keywords
agonist
angiotensin
type
pharmaceutical preparation
receptor
Prior art date
Application number
PCT/SE1999/000262
Other languages
English (en)
French (fr)
Inventor
Lars Fändriks
Anders Pettersson
Anders Hallberg
Original Assignee
A+ Science Invest Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to HU0101411A priority Critical patent/HUP0101411A3/hu
Priority to EP99908017A priority patent/EP1066048A1/en
Priority to BR9908188-1A priority patent/BR9908188A/pt
Priority to KR1020007009295A priority patent/KR20010041211A/ko
Application filed by A+ Science Invest Ab filed Critical A+ Science Invest Ab
Priority to NZ506188A priority patent/NZ506188A/xx
Priority to IL13799099A priority patent/IL137990A0/xx
Priority to MXPA00008172A priority patent/MXPA00008172A/es
Priority to AU27537/99A priority patent/AU755949B2/en
Priority to SK1152-2000A priority patent/SK11522000A3/sk
Priority to CA002319123A priority patent/CA2319123A1/en
Priority to JP2000533135A priority patent/JP2002504516A/ja
Priority to EEP200000481A priority patent/EE200000481A/xx
Publication of WO1999043339A1 publication Critical patent/WO1999043339A1/en
Priority to IS5594A priority patent/IS5594A/is
Priority to NO20004215A priority patent/NO20004215L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/085—Angiotensins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • the present invention relates to a pharmaceutical preparation comprising an angiotensin II type 2 receptor agonist, as well as to a method for prophylaxis and treatment of disorders of the alimentary tract, such as dyspepsia, irritable bowel syndrome and multiple organ failure .
  • Dyspepsia and irritable bowel syndrome are two of the most frequent health conditions encountered in the general population. Epidemiological studies have reported prevalence rates of 25-30% annually if restricted to those who have recurrent abdominal symptoms. The exact mechanisms behind functionally related complaints from the gastrointestinal tract are today unknown. It is believed that they depend on dyscoordination of the functional state in various segments along the gut
  • acid-related dyspepsia One well-known group of dyspeptic symptoms is "acid- related".
  • the definition of acid-related dyspepsia is that there occurs a symptom-relief when stomach acidity is lowered by use of antacids or antisecretagogues .
  • a prerequisite for acid-related dyspeptic symptoms is that luminal acid gets access to the superficial mucosal cells where the sensory receptors are located. This is not the case during normal conditions, as a continuos transport of fluid and bicarbonate provides a neutral compartment at the mucosal surface. This important acid neutralisation on the mucosal surface is dependent on alkaline volume secretion and mixing transport of the luminal con- tents by co-ordinated intestinal wall movements. If the surface neutralisation process is down-regulated, e.g.
  • mucosal acidification may occur allowing for perception of abdominal discomfort either due to direct activation of mucosal acid-receptors, or indirectly by changed wall motility registered by noci- ceptors in the muscle layers of the gut.
  • drugs e.g. non-steriodal antiinflammatory drugs
  • Dyspepsia due to peptic ulcers can be cured by intake or antacids and inhibitors of gastric acid secre- tion. Ulcer-like dyspeptic symptoms without known organic cause are usually sensitive to similar treatment.
  • acid related dyspepsia is defined by the symptom- relief in association with the intake of neutralising agents or inhibition of gastric acid production by use of proton pump inhibitors or histamine type 2 receptor antagonists.
  • the former principle is shortlasting and neutralising drugs must thus be administered repeat- 3 edly during the day.
  • the latter drugs have disadvantages of being expensive and exert a great impact on the gut physiology as the anacid gastric conditions increase the risk for intestinal and/or systemic infections.
  • Proki- netic drugs such as cisapride, modulating gut wall motility; anticholineric compounds inhibiting acid secretion and wall contractions; as well as prostglandine- analogues for preservation of mucosal integrity; are other principles that are utilised for dyspeptic symptoms and IBS, usually with low efficacy and high frequency of side effects. It follows that therapeutic regimens for treatment of functional disorders of the gut are largely lacking and those available are impaired by serious disadvantages . Another condition in which the intestinal mucosapro- tective functions are disturbed is multiple organ failure, MOF. Severe physical stress on the organism (life- threatening critical illness due to e.g.
  • burn injuries or mechanical multitrauma elicits a vasoregulatory response associated with down-regulation of the functional state of non-vital organs, preferentially the mesenteric organs.
  • Distorted mucosa-protective functions are associ ⁇ ated with acid-dependent gastric erosions and bleedings ("haemorrhaged stress-gastritis") and enables gut patho- gens to cross the intestinal mucous and penetrate the mucosal epithelium to eventually spread to systemic compartments via lymphatic and blood vessels. The latter may have severe consequences as the microbial translocation elicits a systemic inflammatory response which, together with the initially compromised systemic circulation, leads to functional failure of various distant organs, e.g.
  • MOF multiple organ failure
  • the treatment of multiple organ failure is very costly and results in long term treatments at intensive care units.
  • Therapeutic efforts in MOF treatment today 4 are mainly aimed at lifesustaimng treatments, such as administration of antibiotics, volume expansion and respiratory assistance.
  • the development of MOF is a mucosal barrier dysfunction and it follows that therapeutic strategies that support mucosaprotective functions of the gut may improve or prevent the condition.
  • the renin-angiotensin system is a regulatory axis, which primarily is involved m circulation homeostasis but has also large impact on gut functions.
  • Angiotensin II is a polypeptide, more specifically an octapeptide, occurring m the sera of mammals, including humans. It is a hormone released when the mammal is sub- jected to stress, and it has a vasoconstrictive and thus blood pressure-raising effect. It also stimulates the secretion of aldosterone from the adrenal glands, which contributes to the blood pressure-raising effect. It is produced m the remn-angiotensm-aldosterone system by conversion of angiotensin I under the influence of the angiotensm-convertmg enzyme, ACE.
  • ACE angiotensm-convertmg enzyme
  • angiotensin II receptor subtypes Although the existence of angiotensin II receptor subtypes has been suspected for some time, definite evidence for angiotensin II receptor heterogeneity has been obtained only with the recently introduced non-peptide angiotensin II receptor antagonists, exemplified with the prototypic compounds DuP 753 (losartan) and PD 123177.
  • the sites having high affinity for DuP 753 are designated as site 1 - angiotensin II type 1 receptors - and those having high affinity for PD 123177 as site 2 - angiotensin II type 2 receptors.
  • the function of angiotensin II type 2 receptors has been unidentified m spite of numerous investigations.
  • angiotensin II-type 2 receptors Activation of angiotensin II-type 2 receptors are involved in the reduction of mesenteric blood flow and the decreased mucosaprotective functional state during various stress conditions.
  • one possible way to pre- 5 vent dyspeptic symptoms and MOF is to block the formation of angiotensin II. This may be done by administration of angiotensin converting enzyme inhibitors (ACE- mhibitors), i.e. compounds that block the formation of angiotensin II. This method has for example been shown to improve mesenteric oxygenation during severe shock.
  • ACE- mhibitors angiotensin converting enzyme inhibitors
  • ACE-mhibitors for treatment of gut disorders is, however, hampered by the fact that they are acting as non-specific enzyme inhibitors, resulting in accumulation of several vasoactive peptides, e.g. brady- kimn, substance P, and endogenous opoids . This may lead to mstable blood pressure regulation as well as an increased risk for allergic manifestations and upper airway irritation.
  • Another way to prevent MOF is to block the angiotensin II type 1 receptors. This is known from the patent application PCT/SE96/00602 (claiming priority from the Swedish patent application No. 9501881-8), wherein the use of angiotensin II type 1 receptor antago&ists for treatment and prophylaxis of MOF is described.
  • the effect of these agonists is a pharmacological specific blockade of angiotensin II type 1 receptors resulting m an increase of gastrointestinal tissue oxygenation in turn reinforcing the mucosal barrier function in the upper gastrointestinal tract.
  • the object of the invention is to provide a pharmaceutical preparation as well as a method for treatment of condition affecting the alimentary tract, such as dyspep- sia, irritable bowel syndrome or multiple organ failure.
  • the invention is based on a new, until now unknown functional role for a subclass of angiotensin II receptors. Selective stimulation of angiotensin II type 2 receptors has been found to elicit a profound activation of gastroduodenal mucosal alkaline secretion and gut motility, effects which lead to a strengthening of the intestinal mucous membrane, thus counteracting conditions of 6 the alimentary tract, such as dyspepsia, irritable bowel syndrome or by multiple organ failure.
  • the present invention relates to a pharmaceutical preparation comprising at least one angiotensin II type 2 receptor agonist or a physiologically acceptable salt thereof.
  • the invention also relates to use of an angiotensin II type 2 receptor agonist or a physiologically acceptable salt thereof for the manufacture of a medicament for treatment and/or prophylaxis of a disorder of the alimentary tract, such as dyspepsia, or of multiple organ failure .
  • the invention relates to a method for treatment and/or prevention of an affection selected from the group consisting of disorders of the alimentary tract, such as dyspepsia, irritable bowel syndrome and/or multiple organ failure in a patient, characterised in that an effective amount of at least one angiotensin II type 2 receptor agonist or a pharmaceutically acceptable salt thereof is administered to the patient.
  • angiotensin II type 2 receptor agonist used herein relates to any compound binding specifically to, and thus stimulating, angiotensin II type 2 receptors .
  • patient used herein relates to all kinds of mammals, including humans, in need of treatment and/or prophylaxis according to the invention.
  • an angiotensin II type 2 receptor agonist or a pharmaceutically acceptable salt thereof may be any substance, derived from natural sources or from synthesis by chemical and/or genetic en- 7 gineering methods, functioning as an angiotensin II type 2 receptor agonist.
  • the agonist may be either a peptide or a peptide mimetic with high selectivity for the angiotensin II type 2 receptor.
  • Examples of peptides functioning as angiotensin II type 2 receptor agonist and thus suitable for use according to the present invention are p-aminophenylalanine 6 - angiotensin II or N- ⁇ -nicotinoyl-Tyr- (N- ⁇ -CBZ-Arg) -Lys- His-Pro-Ile-OH.
  • p-aminophenylalanine 6 -angiotensin II is used, it is preferably administered to the patient directly into the blood. This peptid has a short length of life and will therefore only have an effect for a limited time. This enables an easy control of the effects.
  • a peptide mi- metic may contain elements that enforce steric constraints of a peptide and a peptide mimetic may retain some peptidic character.
  • a peptide mimetic may alternatively be lacking peptidic fragments and consist of an organic molecule.
  • a peptide mimetic can be an organic molecule comprising biaryl, arylheteroaryl, or biheteroaryl fragments that can be attached to a nitrogen containing monocyclic or bicyclic heterocycle by a one, two or three atom linker.
  • a selective angiotensin II type 2 receptor agonist may be an analogue of the non- selective angiotensin II type 2 receptor ligand 5,7- dimethyl-2-ethyl-3- [ [4- [2 (n-butyloxycarbonylsulfonamido) - 5-isobutyl-3-thienyl] phenyl] methyl] -imidazo [4 , 5-b] - pyridine
  • angiotensin II type 2 agonist it is preferable to use a selective angiotensin II type 2 agonist.
  • non- selective angiotensin II type 2 agonists In order to block the negative effects that these non-selective ago- nists may cause due to their influence on the angiotensin II type 1 receptor, it is suitable to combine them with a angiotensin II type 1 receptor antagonist m order to block the angiotensin II type 1 receptor.
  • angio- tensm II type 1 receptor antagonists are known m the art; examples of suitable substances are e.g. described m the patent application PCT/SE96/00602 (claiming priority from the Swedish patent application No. 9501881-8).
  • the pharmaceutical preparations according to the m-vention may be any kind of conventionally used preparations.
  • the pharmaceutical preparations according to the invention may comprise other substances such as e.g. physiologically acceptable additives, such as a solvent, an adjuvant, a carrier and/or a suitable preservative.
  • the pharmaceutical preparations according to the invention have the form of solutions for injection, but they may also be e.g. solutions, suspensions, tablets or capsules intended for oral, sublmgual or rectal ad- ministration.
  • the pharmaceutical preparations according to the invention are particularly useful for prophylaxis and/or treatment of multiple organ failure, dyspepsia and other disorders affecting the alimentary tract. According to the present invention it is thus possible to treat and/or prevent disorders of the alimentary tract or gastrointestinal disorders.
  • disorders include xerostomia, gastro-oesophageal reflux disease, oesophagitis, gastritis, gastroparesis, gastro- duodenal ulcer disease, non ulcer dyspepsia, hyperacidity, pancreatitis, disorders of the biliary tract, coe- liacia, Crohn' s disease, ulcerative colitis, diarrhoea, constipation, irritable bowel disease, colic, dysphagia, obesitas, vomiting, nausea, indigestion and S ogren's syndrome.
  • Example 1 In this m-vivo example, the angiotensin II type 2 receptor agonist p-am ⁇ nophenylalan ⁇ ne 6 -ang ⁇ otensm II, a peptide obtained from SIGMA (Product No. A1811), was used. This agonist was administered intravenously to a chloralose-anesthetized rat prepared for m-situ titra- tion of duodenal mucosal alkaline secretion (the methodological is described by Flemstrom et al in Am. J. Physiol. 1982, 243: G348). It was found that increasing infusion rates of the compound stimulated markedly the mucosal alkalinisation m a dose-dependent fashion, which is illustrated m the table below.
  • the selective angiotensin II type 2 receptor agonist CGP 42112A N- ⁇ -nicotinyl-Tyr- (N- -CZB-Arg) Lys-His-Pro-Ile-OH
  • This agonist was administered intravenously to chlora- lose-anaesthetised rats prepared for in-situ titration as described in Example 1.
  • CGP 42112A was also administered together with a specific angiotensin II type 2 receptor antagonist PD123319 (200 ⁇ g/kg intravenously) .
  • PD123319 a specific angiotensin II type 2 receptor antagonist
  • Example 3 In this in-vivo example, the endogenous ligand of angiotensin II receptors, Angiotensin II, obtained from SIGMA, was used. This agonist was administered intravenously to chloralose-anaesthetised rats prepared for in- situ titration as described in Example 1. It was found that angiotensin II given alone did not increase the duodenal mucosal alkaline secretion, as shown in table 3 below.
  • angiotensin II type 1 receptor antagonist losartan 10 mg/kg intrave- nously
  • angiotensin II infusion stimulated duodenal mucosal alkaline secretion, as evident from the table.
  • L-162,313 infusion (0.3 mg/kg bolus injection i.v., followed by continuos infusion of 0.03 mg/kg x h) increased duodenal mucosal alkaline secretion by 86% compared to baseline.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PCT/SE1999/000262 1998-02-24 1999-02-24 A pharmaceutical preparation comprising an angiotensin ii type 2 receptor agonist, and use thereof WO1999043339A1 (en)

Priority Applications (14)

Application Number Priority Date Filing Date Title
IL13799099A IL137990A0 (en) 1998-02-24 1999-02-24 A pharmaceutical preparation comprising an angiotensin ii type 2 receptor agonist, and use thereof
BR9908188-1A BR9908188A (pt) 1998-02-24 1999-02-24 Preparação farmacêutica, uso de um agonista de receptor de tipo 2 de angiotensina ii ou de um seu sal fisiologicamente aceitável, e, processo para tratamento e/ou prevenção de uma afecção selecionada do grupo consistindo de distúrbios do trato alimentar, tais como dispepsia, sìndrome de intestino irritável e/ou insuficiência múltipla de órgãos em um paciente
KR1020007009295A KR20010041211A (ko) 1998-02-24 1999-02-24 안지오텐신 ιι 타입 2 수용체 효능제를 포함하는 제약제제 및 그의 용도
AU27537/99A AU755949B2 (en) 1998-02-24 1999-02-24 A pharmaceutical preparation comprising an angiotensin II type 2 receptor agonist, and use thereof
NZ506188A NZ506188A (en) 1998-02-24 1999-02-24 A pharmaceutical preparation comprising an angiotensin II type 2 receptor agonist, and use thereof
EP99908017A EP1066048A1 (en) 1998-02-24 1999-02-24 A pharmaceutical preparation comprising an angiotensin ii type 2 receptor agonist, and use thereof
MXPA00008172A MXPA00008172A (es) 1998-02-24 1999-02-24 Preparacion farmacologica que comprende un agonista del receptor tipo 2 de la angiotensina ii y utilizacion de la misma.
HU0101411A HUP0101411A3 (en) 1998-02-24 1999-02-24 A pharmaceutical preparation comprising an angiotensin ii type 2 receptor agonist, and use thereof
SK1152-2000A SK11522000A3 (sk) 1998-02-24 1999-02-24 Farmaceutický prípravok obsahujúci agonistu receptora angiotenzínu ii typu 2 a jeho použitie
CA002319123A CA2319123A1 (en) 1998-02-24 1999-02-24 A pharmaceutical preparation comprising an angiotensin ii type 2 receptor agonist, and use thereof
JP2000533135A JP2002504516A (ja) 1998-02-24 1999-02-24 アンギオテンシンｉｉ型２リセプタ作用薬を含む医薬製剤およびその使用
EEP200000481A EE200000481A (et) 1998-02-24 1999-02-24 Angiotensiin II 2. tüüpi retseptori agonisti sisaldav farmatseutiline preparaat ja selle kasutamine
IS5594A IS5594A (is) 1998-02-24 2000-08-21 Lyfjablanda sem inniheldur gerandefni angíótensínII viðtaka af gerð 2 og notkun hennar
NO20004215A NO20004215L (no) 1998-02-24 2000-08-23 Et farmasøytisk preparat som omfatter en angiotensin II type 2-reseptoragonist, og anvendelse derav

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9800550-7 1998-02-24
SE9800550A SE9800550D0 (sv) 1998-02-24 1998-02-24 A pharmaceutical preparation comprising an angiotensin II type 2 receptor agonist, and use thereof

Publications (1)

Publication Number Publication Date
WO1999043339A1 true WO1999043339A1 (en) 1999-09-02

Family

ID=20410283

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/SE1999/000262 WO1999043339A1 (en) 1998-02-24 1999-02-24 A pharmaceutical preparation comprising an angiotensin ii type 2 receptor agonist, and use thereof

Country Status (18)

Country Link
EP (1) EP1066048A1 (no)
JP (1) JP2002504516A (no)
KR (1) KR20010041211A (no)
CN (1) CN1291104A (no)
AU (1) AU755949B2 (no)
BR (1) BR9908188A (no)
CA (1) CA2319123A1 (no)
EE (1) EE200000481A (no)
HU (1) HUP0101411A3 (no)
ID (1) ID26639A (no)
IL (1) IL137990A0 (no)
IS (1) IS5594A (no)
MX (1) MXPA00008172A (no)
NO (1) NO20004215L (no)
NZ (1) NZ506188A (no)
SE (1) SE9800550D0 (no)
SK (1) SK11522000A3 (no)
WO (1) WO1999043339A1 (no)

Cited By (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001043761A2 (en) * 1999-12-16 2001-06-21 University Of Southern California Methods for treating and preventing damage to mucosal tissue
US6821953B1 (en) 1999-12-16 2004-11-23 University Of Southern California Methods for treating and preventing damage to mucosal tissue
US7652054B2 (en) 2001-05-31 2010-01-26 Vicore Pharma Ab Tricyclic compounds useful as angiotensin II agonists
US8067418B2 (en) 2005-04-12 2011-11-29 Vicore Pharma Ab Tricyclic angiotensin II agonists
US8080571B2 (en) 2005-04-12 2011-12-20 Vicore Pharma Ab Tricyclic angiotensin II agonists
EP2455388A1 (en) 2010-11-23 2012-05-23 LanthioPep B.V. Novel angiotensin type 2 (AT2) receptor agonists and uses thereof.
US8357710B2 (en) 2005-04-12 2013-01-22 Vicore Pharma Ab Bicyclic angiotensin II agonists
WO2013158628A1 (en) * 2012-04-16 2013-10-24 New York University Modulation of angiotensin ii peceptors for the prevention and treatment of cerebral malaria
US8835471B2 (en) 2010-06-11 2014-09-16 Vicore Pharma Ab Use of angiotensin II agonists
WO2016139475A1 (en) 2015-03-02 2016-09-09 Vicore Pharma Ab Angiotensin ii receptor agonist for treating pulmonary fibrosis
WO2017221012A1 (en) 2016-06-21 2017-12-28 Vicore Pharma Ab Methods and compositions for preventing or reducing the risk of cancer treatment-related cardiotoxicity
WO2020095042A1 (en) 2018-11-07 2020-05-14 Vicore Pharma Ab New composition comprising amorphous nanoporous silica particles
WO2021023698A1 (en) 2019-08-02 2021-02-11 Lanthiopep B.V Angiotensin type 2 (at2) receptor agonists for use in the treatment of cancer
WO2021053344A1 (en) 2019-09-20 2021-03-25 Vicore Pharma Ab New compounds
WO2021186180A1 (en) 2020-03-20 2021-09-23 Vicore Pharma Ab Imidazolyl thiopehene sulfonyl carbamates for use in the treatment of diseases associated with angiotensin ii
WO2021186185A1 (en) 2020-03-19 2021-09-23 Vicore Pharma Ab Novel compounds useful in the treatment and/or prevention of a disease, disorder or condition associated with angiotensin ii
WO2021214488A1 (en) 2020-04-24 2021-10-28 Vicore Pharma Ab New dry powder composition for peroral administration
WO2021214487A1 (en) 2020-04-24 2021-10-28 Vicore Pharma Ab New delayed release composition for peroral administration
WO2021214486A1 (en) 2020-04-24 2021-10-28 Vicore Pharma Ab New capsule composition for peroral administration
GB202115303D0 (en) 2021-10-25 2021-12-08 Vicore Pharma Ab New formulation
WO2022049372A1 (en) 2020-09-01 2022-03-10 Vicore Pharma Ab Novel compounds for use in the treatment of diseases associated with angiotensin ii
WO2022200786A1 (en) 2021-03-23 2022-09-29 Vicore Pharma Ab Selective angiotensin ii receptor ligands
WO2022200787A1 (en) 2021-03-23 2022-09-29 Vicore Pharma Ab Selective angiotensin ii receptor ligands
WO2022200785A1 (en) 2021-03-23 2022-09-29 Vicore Pharma Ab Selective angiotensin ii receptor ligands
WO2023281271A1 (en) 2021-07-09 2023-01-12 Vicore Pharma Ab New selective angiotensin ii compounds
WO2023152503A1 (en) 2022-02-10 2023-08-17 Vicore Pharma Ab Use of buloxibutid for the treatment of idiopathic pulmonary fibrosis
US11819494B2 (en) 2022-02-10 2023-11-21 Vicore Pharma Ab Treatment of idiopathic pulmonary fibrosis

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2631491C (en) * 2005-12-14 2015-02-24 Ambrx, Inc. Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5444067A (en) * 1993-08-30 1995-08-22 Merck & Co., Inc. Pharmaceutical treatment methods using angiotensin II receptor agonists bearing a thiophene moiety
WO1996014060A1 (en) * 1994-11-04 1996-05-17 Marklund Stefan L Use of receptor agonists to stimulate superoxide dismutase activity
WO1996036336A1 (en) * 1995-05-19 1996-11-21 Astra Aktiebolag (Publ) New pharmacological use of aii-receptor antagonists
WO1996039164A1 (en) * 1995-06-06 1996-12-12 The University Of Southern California Use of angiotensin ii type 2 receptor agonists in tissue repair
WO1997000070A1 (en) * 1995-06-19 1997-01-03 Astra Aktiebolag Novel medical use

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5444067A (en) * 1993-08-30 1995-08-22 Merck & Co., Inc. Pharmaceutical treatment methods using angiotensin II receptor agonists bearing a thiophene moiety
WO1996014060A1 (en) * 1994-11-04 1996-05-17 Marklund Stefan L Use of receptor agonists to stimulate superoxide dismutase activity
WO1996036336A1 (en) * 1995-05-19 1996-11-21 Astra Aktiebolag (Publ) New pharmacological use of aii-receptor antagonists
WO1996039164A1 (en) * 1995-06-06 1996-12-12 The University Of Southern California Use of angiotensin ii type 2 receptor agonists in tissue repair
WO1997000070A1 (en) * 1995-06-19 1997-01-03 Astra Aktiebolag Novel medical use

Cited By (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001043761A3 (en) * 1999-12-16 2002-03-07 Univ Southern California Methods for treating and preventing damage to mucosal tissue
US6821953B1 (en) 1999-12-16 2004-11-23 University Of Southern California Methods for treating and preventing damage to mucosal tissue
US7176183B2 (en) 1999-12-16 2007-02-13 University Of Southern California Methods for treating and preventing damage to mucosal tissue
WO2001043761A2 (en) * 1999-12-16 2001-06-21 University Of Southern California Methods for treating and preventing damage to mucosal tissue
US7652054B2 (en) 2001-05-31 2010-01-26 Vicore Pharma Ab Tricyclic compounds useful as angiotensin II agonists
US8124638B2 (en) 2001-05-31 2012-02-28 Vicore Pharma Ab Tricyclic compounds useful as angiotensin II agonists
US8357710B2 (en) 2005-04-12 2013-01-22 Vicore Pharma Ab Bicyclic angiotensin II agonists
US8067418B2 (en) 2005-04-12 2011-11-29 Vicore Pharma Ab Tricyclic angiotensin II agonists
US8080571B2 (en) 2005-04-12 2011-12-20 Vicore Pharma Ab Tricyclic angiotensin II agonists
US8835471B2 (en) 2010-06-11 2014-09-16 Vicore Pharma Ab Use of angiotensin II agonists
WO2012070936A1 (en) 2010-11-23 2012-05-31 Lanthiopep B.V. Novel angiotensin type 2 (at2) receptor agonists and uses thereof
EP2455388A1 (en) 2010-11-23 2012-05-23 LanthioPep B.V. Novel angiotensin type 2 (AT2) receptor agonists and uses thereof.
US9290540B2 (en) 2010-11-23 2016-03-22 Lanthio Pep B.V. Angiotensin Type 2 (AT2) receptor agonists and uses thereof
US9707268B2 (en) 2010-11-23 2017-07-18 Lanthiopep B.V. Angiotensin type 2 (AT2) receptor agonists and uses thereof
US10214563B2 (en) 2010-11-23 2019-02-26 Lanthiopep B.V. Angiotensin type 2 (AT2) receptor agonists and uses thereof
WO2013158628A1 (en) * 2012-04-16 2013-10-24 New York University Modulation of angiotensin ii peceptors for the prevention and treatment of cerebral malaria
WO2016139475A1 (en) 2015-03-02 2016-09-09 Vicore Pharma Ab Angiotensin ii receptor agonist for treating pulmonary fibrosis
WO2017221012A1 (en) 2016-06-21 2017-12-28 Vicore Pharma Ab Methods and compositions for preventing or reducing the risk of cancer treatment-related cardiotoxicity
WO2020095042A1 (en) 2018-11-07 2020-05-14 Vicore Pharma Ab New composition comprising amorphous nanoporous silica particles
WO2021023698A1 (en) 2019-08-02 2021-02-11 Lanthiopep B.V Angiotensin type 2 (at2) receptor agonists for use in the treatment of cancer
WO2021053344A1 (en) 2019-09-20 2021-03-25 Vicore Pharma Ab New compounds
WO2021186185A1 (en) 2020-03-19 2021-09-23 Vicore Pharma Ab Novel compounds useful in the treatment and/or prevention of a disease, disorder or condition associated with angiotensin ii
WO2021186180A1 (en) 2020-03-20 2021-09-23 Vicore Pharma Ab Imidazolyl thiopehene sulfonyl carbamates for use in the treatment of diseases associated with angiotensin ii
US11654115B2 (en) 2020-04-24 2023-05-23 Vicore Pharma Ab Delayed release composition for peroral administration
WO2021214488A1 (en) 2020-04-24 2021-10-28 Vicore Pharma Ab New dry powder composition for peroral administration
WO2021214487A1 (en) 2020-04-24 2021-10-28 Vicore Pharma Ab New delayed release composition for peroral administration
WO2021214486A1 (en) 2020-04-24 2021-10-28 Vicore Pharma Ab New capsule composition for peroral administration
US11844868B2 (en) 2020-04-24 2023-12-19 Vicore Pharma Ab Dry powder composition for peroral administration
EP4218737A1 (en) 2020-04-24 2023-08-02 Vicore Pharma AB New delayed release composition for peroral administration
WO2022049372A1 (en) 2020-09-01 2022-03-10 Vicore Pharma Ab Novel compounds for use in the treatment of diseases associated with angiotensin ii
WO2022200785A1 (en) 2021-03-23 2022-09-29 Vicore Pharma Ab Selective angiotensin ii receptor ligands
WO2022200787A1 (en) 2021-03-23 2022-09-29 Vicore Pharma Ab Selective angiotensin ii receptor ligands
WO2022200786A1 (en) 2021-03-23 2022-09-29 Vicore Pharma Ab Selective angiotensin ii receptor ligands
WO2023281271A1 (en) 2021-07-09 2023-01-12 Vicore Pharma Ab New selective angiotensin ii compounds
GB202115303D0 (en) 2021-10-25 2021-12-08 Vicore Pharma Ab New formulation
WO2023152503A1 (en) 2022-02-10 2023-08-17 Vicore Pharma Ab Use of buloxibutid for the treatment of idiopathic pulmonary fibrosis
US11819494B2 (en) 2022-02-10 2023-11-21 Vicore Pharma Ab Treatment of idiopathic pulmonary fibrosis

Also Published As

Publication number Publication date
CA2319123A1 (en) 1999-09-02
BR9908188A (pt) 2000-10-24
AU755949B2 (en) 2003-01-02
EE200000481A (et) 2002-02-15
MXPA00008172A (es) 2002-06-21
KR20010041211A (ko) 2001-05-15
NO20004215L (no) 2000-09-18
EP1066048A1 (en) 2001-01-10
IL137990A0 (en) 2001-10-31
NO20004215D0 (no) 2000-08-23
SK11522000A3 (sk) 2001-04-09
NZ506188A (en) 2003-04-29
ID26639A (id) 2001-01-25
SE9800550D0 (sv) 1998-02-24
IS5594A (is) 2000-08-21
AU2753799A (en) 1999-09-15
JP2002504516A (ja) 2002-02-12
CN1291104A (zh) 2001-04-11
HUP0101411A3 (en) 2002-11-28
HUP0101411A2 (hu) 2002-03-28

Similar Documents

Publication Publication Date Title
AU755949B2 (en) A pharmaceutical preparation comprising an angiotensin II type 2 receptor agonist, and use thereof
CA2321700C (en) Pharmaceutical composition for the treatment of functional dyspepsia and/or irritable bowel syndrome and new use of substances therein
EP1789067B1 (en) Use of growth hormone secretagogues for stimulating the motility of the gastrointestinal system
Kirkegaard et al. Epidermal growth factor inhibits cysteamine-induced duodenal ulcers
Mason et al. Cyclosporine 1 and the renin-angiotensin system.
Sakaguchi et al. Inhibition of tissue angiotensin converting enzyme. Quantitation by autoradiography.
US8664177B2 (en) Peptide compositions and methods for treating patients
Naesdal et al. Effect of omeprazole, a substituted benzimidazole, on 24-h intragastric acidity in patients with peptic ulcer disease
HUE027280T2 (en) Angiotensin II Receptor Antagonists to Treat High Blood Pressure in Cats
Itoh et al. Gastric ulcer treatment with intravenous human epidermal growth factor: a double‐blind controlled clinical study
Khalil et al. VIP modulates substance P-induced plasma extravasation in vivo
EP1827476B1 (en) Use of bombesin/gastrin-releasing peptide antagonist for the treatment of sepsis, septic shock, acute lung injury or rheumatoid arthritis
Stöckmann et al. Long-term treatment of patients with endocrine gastrointestinal tumours with the somatostatin analogue SMS 201-995
Kirkegaard et al. Exocrine secretion of epidermal growth factor from Brunner's glands. Stimulation by VIP and acetylcholine
Konturek et al. Effect of ranitidine, a new H 2-antagonist, on gastric and pancreatic secretion in duodenal ulcer patients
Coraggio et al. Clinical, controlled trial of somatostatin with ranitidine and placebo in the control of peptic hemorrhage of the upper gastrointestinal tract
EP0840607B1 (en) Novel medical use
JPS60231618A (ja) 胃腸潰瘍の治癒促進用製剤組成物
Nakabayashi et al. Marked improvement of diabetic diarrhea with the somatostatin analogue octreotide
Bertaccini et al. Effects of physalaemin on some exocrine secretions of dogs and rats
CZ20003080A3 (cs) Farmaceutický prostředek obsahující agonistu receptoru pro angiotensin II 2.typu a jeho použití
Nussberger et al. Chronic treatment of hypertensive patients with converting enzyme inhibitors
RU2147884C1 (ru) Способ лечения язвенной болезни желудка и двенадцатиперстной кишки
Brunner et al. The clinical application of converting enzyme inhibitors
DeForrest et al. Blood pressure lowering and renal hemodynamic effects of fosinopril in conscious animal models

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 99803230.1

Country of ref document: CN

AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AT AT AU AZ BA BB BG BR BY CA CH CN CU CZ CZ DE DE DK DK EE EE ES FI FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 1999908017

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 27537/99

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2319123

Country of ref document: CA

Ref document number: 2319123

Country of ref document: CA

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 11522000

Country of ref document: SK

WWE Wipo information: entry into national phase

Ref document number: 506188

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 506378

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 137990

Country of ref document: IL

Ref document number: PA/a/2000/008172

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: PV2000-3080

Country of ref document: CZ

Ref document number: 1020007009295

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 09601616

Country of ref document: US

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1999908017

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1020007009295

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: PV2000-3080

Country of ref document: CZ

WWG Wipo information: grant in national office

Ref document number: 27537/99

Country of ref document: AU

WWW Wipo information: withdrawn in national office

Ref document number: 1999908017

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1020007009295

Country of ref document: KR

WWR Wipo information: refused in national office

Ref document number: PV2000-3080

Country of ref document: CZ